1. Macitentan, a derivative of the endothelin receptor antagonist bosentan, reduced morbidity from pulmonary arterial hypertension compared to placebo.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Medical therapies for pulmonary arterial hypertension (PAH) generally work by reducing the pressure in the pulmonary vasculature. Endothelin receptor antagonists accomplish this by...
In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week.
Riociguat for the Treatment of Pulmonary Arterial Hypertension
In this phase III, double-blinded randomized control trial, investigators randomized patients with pulmonary arterial hypertension (n = 443) to riociguat, a guanylate...
1. A new link has been found between KCNK3 gene mutations and pulmonary arterial hypertension.
2. The mutations identified affect the ability of the KCNK3 ion channel to conduct current.
3. A drug known to stimulate KCNK3 channels can restore conductivity of some of the mutant channels in vitro.